“We are proud to present a comprehensive agenda that provides expert interpretation for all oncology professionals on the latest emerging data that can improve treatment and quality of life for cancer patients." - Phil Talamo, pres., PER®
Plainsboro, N.J. (PRWEB) October 10, 2016
Physicians’ Education Resource®, LLC (PER®), in partnership with Pharmacy Times Continuing Education™ (PTCE™), is proud to announce the full conference agenda, along with two new specialized learning tracks, for this year’s 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting. The conference takes place November 9 to 11 at the New York Marriott Marquis.
The Chemotherapy Foundation Symposium™, organized by PER Events and sponsored by PER®, each year attracts more than 2,000 oncologists, hematologists and other health care professionals from around the world to learn about state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios from leading experts.
“Our goal at PER® is to advance cancer care through professional education for the full cancer treatment team, and the Chemotherapy Foundation Symposium™ remains the premier educational conference for the cancer care community,” said Phil Talamo, president of PER®. “We are proud to present a comprehensive agenda that provides expert interpretation for all oncology professionals on the latest emerging data that can improve treatment and quality of life for cancer patients. With this year’s general session room, two breakout specialty tracks, and triple-accreditation for physicians, nurses and pharmacists, the 2016 meeting will truly be the most comprehensive and impactful oncology CME/CE conference of the year.”
For 2016, the Chemotherapy Foundation Symposium™ has added two certified continuing education tracks. The “Nursing Track” will focus on innovative nursing practices and the “How I Do It Track” will focus on personal case studies from experts dealing with challenging diagnosis and treatment scenarios. Highlights of the Nursing Track will include presentations on community-based participatory research, updates on immunotherapy, when to discuss palliative care and the use of text messaging to improve oral adherence. For more information, visit their website here. The How I Do It Track will offer advice on treating common malignancies, such as incorporating molecular profiling, managing progressive brain metastases and immune-related toxicities, along with other notable topics. For more information, click here.
Key presentations of this year’s meeting include:
- Clinical Applications and Next Steps to Apply Biomarkers With the Use of Immunotherapies
- Emerging Targeted Treatment Approaches in Lymphoma
- Triple-Negative Breast Cancer: A Look at the Evidence and the Future of Care
- Emerging Compounds for the Treatment of Chronic Lymphocytic Leukemia
- A Look at the Near-Future of Melanoma Treatment
- Evolving Paradigm Shifts in TKI Sequencing for Renal Cell Carcinoma
This year will also focus on three Medical Crossfire® panel discussions, leveraging the fast-paced and well-known legacy learning format of PER® to exchange expert perspectives on best treatment practices. This year’s Medical Crossfire® segments will focus on the impact of PD-L1 positivity on leveraging immunotherapy in lung cancer, the evolving role of minimal residual disease across hematologic malignancies and whether the use anthracyclines in treating breast cancer will change in the future.
In addition, the 2016 Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® keynote speaker is Atul Butte, M.D., Ph.D., a global expert in clinical informatics, a field that is guiding practitioners toward delivering more effective chemotherapy and other treatments for cancer and a range of other diseases. Dr. Butte’s presentation, “Translating a Trillion Points of Data into Therapies, Diagnostics, and New Insights into Disease,” will provide insight into the future of personalized oncology treatments.
Nursing and pharmacy accreditation activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PER® and PTCE™. PER® is accredited by the ACCME to provide continuing medical education for physicians. PER® is approved by the California Board of Registered Nursing, Provider #16669 for 22.0 Contact Hours. PTCE™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for a maximum of 22.0 contact hours (0.22 CEUs).
PER® serves the oncology health care community, including physicians, nurses, nurse practitioners, physician assistants, pharmacists and other health care providers who are involved in the treatment and management of patients with cancer.
Since 1995, PER® has been the educational resource of choice for live and online activities focusing on oncology and hematology. PER® provides high-quality, evidence-based activities featuring leading national and international faculty with a focus on practice-changing advances and standards of care in treatment and disease management. Activities also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection, and practice management.
With rapid advances occurring in the field of oncology, understanding how to use molecular data to diagnose and stage patients, selecting the most appropriate candidates for novel therapeutic agents, individualizing treatment based on tumor type, and referring patients to clinical trials will continue to ensure the highest level of patient care is provided.
PER® serves the oncology health care community, including physicians, fellows, advanced practice nurses, nurses, physician assistants, pharmacists and researchers. PER® is part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc., family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
Pharmacy Times Continuing Education™ (PTCE™) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Activities produced by PTCE™ include live meetings and webinars, as well as home study formats (print- and internet-based). Using their long-standing relationship with the journal, Pharmacy Times®, PTCE™ enjoys a wide distribution of our continuing pharmacy education activities to more than 250,000 practicing pharmacists. PTCE™ is also part of the Michael J. Hennessy Associates, Inc. Learn more at http://www.pharmacytimes.com and http://www.mjhassoc.com.
Media Contact for PER:
Becky Taylor, 609-240-6886, becky(at)btaylorpa(dot)com